Pancreatic cancer diagnosis usually involves several tests, with each providing different information. This article explains how blood tests, CA 19-9, CT, abdominal ultrasound, MRI with MRCP, endoscopic ultrasound, and biopsy are used to investigate suspicious findings. It also explains what each test can show, when further testing may be needed, and how doctors use the results to confirm the diagnosis and assess the extent of the disease before treatment planning.

Pancreatic Cancer Diagnosis: Tests, Imaging and Biopsy

Diagnosing pancreatic cancer usually involves several tests because each one provides different information. Blood tests can identify changes that may be linked to the disease, while imaging helps locate and assess a suspicious tumour. Endoscopic ultrasound or a biopsy may be needed for a closer examination or to obtain tissue for confirmation. Together, these findings help doctors determine whether pancreatic cancer is present, assess the extent of the disease, and decide on the most appropriate next steps [1].

Pancreatic Cancer Diagnostic Pathway

The diagnostic process usually begins with a medical assessment and then moves to blood tests and imaging. Additional tests, such as MRI, endoscopic ultrasound, or a biopsy, may be recommended when earlier results need further clarification.

• Medical history and physical examination, including assessment for signs such as jaundice. 
• Blood tests, including liver function tests and, in some cases, CA 19-9. 
• Pancreatic-protocol CT to assess the pancreas and look for signs of spread. 
• MRI or endoscopic ultrasound when further clarification is needed. 
• Tissue sampling when a biopsy is required to confirm the diagnosis before treatment. 
• Pathology review to identify whether cancer is present and determine the tumour type.

The pancreatic cancer diagnostic pathway, from first assessment to a confirmed result.

Blood Tests and Tumor Markers in Pancreatic Cancer Diagnosis

Blood tests cannot diagnose pancreatic cancer on their own, but they can provide useful information about how the body is functioning. They may show changes associated with bile duct blockage, jaundice, anaemia, or changes in blood sugar.

• Liver function tests and bilirubin often rise when a tumour in the head of the pancreas blocks the bile duct, producing jaundice.
• CA 19-9 is the main tumour marker used, most valuable for monitoring rather than as a standalone diagnostic or screening test [3].
• Other findings, such as anaemia or changes in blood sugar, can add context to the overall picture.

CA 19-9 can be normal even when pancreatic cancer is present because some people do not produce this marker due to their Lewis antigen status. It can also rise in non-cancerous conditions, including bile duct blockage. Blood tests can help identify problems such as bile duct blockage and provide a baseline CA 19-9 level that may later be monitored, but they cannot locate a tumour or confirm pancreatic cancer. For this reason, the results are interpreted alongside imaging and other clinical findings [3].

Diagnostic Imaging in Pancreatic Cancer Evaluation

Imaging is central to pancreatic cancer diagnosis because it can identify a suspicious mass, assess its size and location, and look for signs that the disease has spread. A pancreatic-protocol CT is commonly used first, while MRI and endoscopic ultrasound may be added when more detailed information is needed [1]. 

How the main diagnostic tests complement each other.

CT Scan for Pancreatic Evaluation

A contrast-enhanced, pancreatic-protocol CT is one of the main imaging tests used to assess suspected pancreatic cancer. It shows the tumour's location and size, and importantly, how it relates to the major blood vessels around the pancreas, which helps doctors assess whether surgery may be possible. CT is particularly useful for assessing the size and location of a pancreatic tumour, its relationship with nearby blood vessels, and whether there are signs that the cancer has spread. However, very small or subtle tumours may be difficult to detect, and microscopic spread cannot be seen directly on imaging. If the CT result is unclear or suspicion remains high, further tests such as MRI or endoscopic ultrasound may be recommended [1].

Abdominal Ultrasound

A standard abdominal ultrasound is often the first scan when someone has jaundice or upper abdominal pain, because it is quick, widely available, and involves no radiation. It is good at spotting a blocked, dilated bile duct, which can be the first sign that something is obstructing flow near the pancreas.

• Gives an early, accessible look at the pancreas and bile ducts.
• Bowel gas and body habitus often blur the view, especially of the pancreatic tail.
• If the ultrasound does not clearly explain the cause of the symptoms or bile duct blockage, further imaging such as CT or MRI may be needed.

Pancreatic MRI and MRCP

MRI provides a detailed look at pancreatic lesions and is particularly useful for characterising findings that CT leaves uncertain. Its companion sequence, MRCP, maps the pancreatic and bile ducts without any instrument, which helps show where and how a duct is blocked [1].

• Characterises suspicious or indeterminate lesions seen on CT.
• MRCP outlines the pancreatic and bile ducts to pinpoint a blockage.
• Can reveal small liver deposits that a CT scan may not show [1].
• Advantages: no radiation, excellent soft-tissue detail, and a duct map from MRCP without any instrument.
• Limitations: less available than CT, longer scan times, and harder for patients who cannot lie still or have certain implants.
• When it is added: to clarify an uncertain CT, characterise a small liver lesion, or plan around a blocked duct.

Endoscopic Ultrasound and Tissue Sampling in Pancreatic Cancer Diagnosis

Endoscopic ultrasound, or EUS, places an ultrasound probe on the tip of an endoscope right next to the pancreas, giving a much closer view than scans taken from outside the body. This makes it especially good at finding small tumours and at examining findings that remain unclear after CT or MRI. EUS is particularly useful when a lesion is small or unclear, when other scans show indirect signs of a possible tumour, or when a tissue sample is needed. It provides a close view of the pancreas and can allow a biopsy to be performed during the same procedure. Because it is an invasive procedure and its accuracy depends partly on operator expertise, it is used selectively rather than as a first test for everyone [2].

Biopsy and Pathology in Pancreatic Cancer Diagnosis

A biopsy is considered when a tissue diagnosis will change what happens next, for example before chemotherapy or when imaging alone is not conclusive. When a biopsy is needed, it is commonly performed during EUS using a fine needle to obtain cells or a small tissue sample from the suspicious area [4].

• A pathologist examines the tissue to confirm cancer and identify its type.
• Histology can also flag features that guide later treatment choices.

A positive biopsy confirms the diagnosis, but a negative or inconclusive result does not always rule cancer out, because a small needle can miss the target. In that situation the sample may be repeated or the case reviewed alongside the imaging. The pathology report confirms the diagnosis and identifies the tumour type, providing information that may help guide treatment decisions [4].

Diagnostic Confirmation and Further Evaluation

Once the necessary tests have been completed, the medical team reviews the results to confirm the diagnosis and assess the extent of the disease [1].

• Confirmation of the diagnosis and tumour type, when tissue has been obtained.
• Assessment of how far the cancer has spread. 
• Evaluation of whether the tumour may be removed with surgery. 
• Discussion of the findings and next steps with the specialist team.

This combined evaluation allows the multidisciplinary team to determine the exact stage of the cancer and recommend a personalized treatment plan tailored to the patient's overall health and specific condition.

References

1. Corallo, C., Al-Adhami, A. S., Jamieson, N., Valle, J., Radhakrishna, G., Moir, J., & Albazaz, R. (2025). An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. The British journal of radiology, 98(1165), 13–26.

2.  Farr, K. P., Moses, D., Haghighi, K. S., Phillips, P. A., Hillenbrand, C. M., & Chua, B. H. (2022). Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities. Cancers, 14(10), 2539. 

3. Janga, L. S. N., Sambe, H. G., Yasir, M., Man, R. K., Gogikar, A., Nanda, A., & Mohammed, L. (2023). Holistic Understanding of the Role of Carbohydrate Antigen 19-9 in Pancreatic Cancer Screening, Early Diagnosis, and Prognosis: A Systematic Review. Cureus, 15(8), e44382. 

4. El-Nady, M. A., Ead, K. A., Haridy, M. A., Shaheen, N., Nashwan, A. J., Abdelwahid, S. R., Mohammed, M. F., Mohamed, O., Sawy, S. S., Abdelrazzak, E., & Hassan, A. M. (2024). Role of Endoscopic Ultrasound in Staging and Vascular Assessment of Pancreatic Cancer. Cureus, 16(2), e53988

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained